Matricelf

Matricelf LT Debt/Equity

Long-Term Debt to Equity Ratio of Matricelf (MTLF.TA) as of Nov 4, 2026.

LT Debt/Equity

0.00

Last updated:

Long-Term Debt to Equity Ratio of Matricelf is 2025 0.00 . Long-Term Debt to Equity Ratio of Matricelf was 2024 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Matricelf Stock analysis

What does Matricelf do? Matricelf Ltd. is a biotechnology company that engages in research and development of a platform for autologous matrix and cell implants in the field of regenerative medicine and tissue engineering. The firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The firm focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University. Matricelf is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Matricelf stock

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Matricelf since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Matricelf with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Matricelf

All Key Metrics — Matricelf